Table 1

Characteristics	Total (N=355)	Non-INSTIs (n=247)	INSTIs (n=108)
Gender-n (%)
Male	332 (94)	227 (92)	105 (97)
Female	23 (6)	20 (8)	3 (3)
Ages-median ± IQR	31 (26, 39)	30 (26, 40)	34 (27, 39)
Route of HIV transmission-n (%)
Homosexual	244 (68.7)	172 (69.6)	72 (66.7)
Bisexual	9 (2.5)	6 (2.4)	3 (2.8)
Heterosexual	49 (13.8)	34 (13.8)	15 (13.9)
Others	53 (14.9)	35 (14.2)	18 (16.7)
CD4⁺ T cell count (cells/μL)-median (IQR)	346 (280, 456)	343 (279, 443)	351 (284, 487)
HIV-1 RNA (log₁₀ copies/mL)-median (IQR)	4.5 (4.2, 4.9)	4.5 (4.2, 4.9)	4.6 (4.3, 5.1)
ART regimes-n (%)
2 NRTIs+1 NNRTIs	229 (92.7)	229 (92.7)	NA
2NRTIs+1 PIs	17 (6.9)	17 (6.9)	NA
1NRTIs+1NNRTIs+ AZV	1 (0.4)	1 (0.4)	NA
Based-RAL regimens	19 (17.6)	NA	19 (17.6)
B/F/TAF	26 (24.1)	NA	26 (24.1)
Based-DTG regimens	44 (40.7)	NA	44 (40.7)
E/c/F/TAF	19 (17.6)	NA	19 (17.6)
HBsAg (+)-n (%)	14 (3.9)	11 (4.5)	3 (2.8)
HCV-Ab (+)-n (%)	4 (1.1)	3 (1.2)	1 (0.9)

Table 1: Baseline clinical characteristics of study populations with baseline CD4+ T cell count ≥ 200 cells/µL in the INSTIs group and non-INSTIs group

INSTIs, integrase strand transfer inhibitors; IQR, interquartile ranges; ART, antiretroviral therapy; RNA, Ribonucleic acid; NRTIs, nucleoside reverse transcriptase inhibitors; NNRTIs, non-nucleoside reverse transcriptase inhibitors; PIs, protease inhibitors; AZV, azvudine; RAL, Raltegravir; B/F/TAF, Bictegravir/Emtricitabine/Tenofovir alafenamide; DTG, dolutegravir; E/c/F/TAF, Elvitegravir/cobicistat/Emtricitabine/Tenofovir alafenamide; HBsAg, hepatitis B virus surface antigen; HCV-Ab, hepatitis C virus antibody

Table 2

Time from ART initiation(weeks)	Changes in weight					p value
	(kg) by regimens
	DTG (n=44)	BIC (n=19)	RAL (n=26)	EVG (19)	DTG vs. BIC
4	-0.25±1.59	0.84±3.47	-0.29±1.79	0.46±1.64		0.123
12	1.06±2.48(*)	1.10±5.09	0.61±2.75	2.34±2.58(*)		0.982
24	1.92±1.94(***)	3.00±5.66	1.10±2.88	3.70±3.64(*)		0.483
48	2.88±3.35(****)	3.46±6.26(**)	2.68±3.82(*)	2.20±4.30		0.732

Table 2: Body weight change INSTIs-based regimens during ART 48 weeks

^*, compared with week 4; ^*, p<0.05; ^**, p<0.01, ^***, p<0.001; ^****, p<0.0001.

Table 3

Characteristics	Non-INSTIs (n=22)	INSTIs (n=21)	P value
Gender-n (%)
Male	20 (91)	21 (100)	0.512
Female	2 (9)	0	0.512
Ages-median ± IQR	35 (27, 48)	35 (29, 47)	0.834
BMI (kg/m²)-mean±SD	22.1±3.1	22.0±3.2	0.92
CD4⁺ T cell count (cells/μL)-median (IQR)	340 (294, 421)	395 (251, 652)	0.028
HIV-1 RNA (log₁₀ copies/mL)-median (IQR)	4.5 (4.3, 5.0)	4.7 (4.4, 5.0)	0.638

Table 3: Clinical characteristics of PLWH experiencing severe weight gain

INSTIs, Integrase strand transfer inhibitors; IQR, interquartile ranges; SD, standard deviation; BMI, body mass index; RNA, Ribonucleic acid

Table 4

Time from ART initiation(weeks)	Changes in weight					p value
	(kg) by regimens
	DTG	BIC	RAL	EVG	DTG vs. BIC
4	0.39±2.36	0.71±3.20	0.43±2.01	0.59±1.43		0.873
12	1.96±3.17(**)	1.98±3.29	2.11±4.08	2.03±2.46(*)		0.976
24	2.75±3.66(***)	4.36±5.29(**)	2.88±5.06(*)	3.46±4.04(*)		0.059
48	4.62±5.28(****)	4.90±6.38(***)	4.17±5.57(**)	3.89±5.30(*)		0.355

Supplementary Table 1: Body weight change INSTIs-based regimens during ART 48 weeks

Tables at a glance

Table 1

Table 2

Table 3

Table 4

Figures at a glance

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5

Figure 6

Figure 7

FIGURE 1

Figure 1: Body weight changes and the prevalence of obesity after ART between INSTIs group and non-INSTIs group. A, absolute body weight change; B, body weight change compared to baseline; C, the prevalence of obesity. *, p<0.05; ***, p<0.001; ****, p<0.0001

FIGURE 2

Figure 2: The number and percentage of severe weight gain between the INSTIs group and the non-INSTIs group in ART 96 weeks. a-b, the number of severe weight gain and non-severe weight gain in the non-INSTIs group and INSTIs group respectively. c, the percentage of severe weight gain between non-INSTIs and INSTIs.

FIGURE 3

Figure 3: Multivariate analyses for severe weight gain based on INSTIs or non NSTIs regimens.

FIGURE 4

Supplementary Figure 1: Body weight changes and the prevalence of obesity after ART between INSTIs group and non-INSTIs group. A, absolute body weight change; B, body weight change compared to baseline; C, the prevalence of obesity. *, p<0.05; ***, p<0.001; ****, p<0.0001

FIGURE 5

Supplementary Figure 2: The subgroups analysis of body weight changes in 474 different INSTI regimens during ART 48 weeks. A, absolute weight changes; B, 475 weight gain compared to baseline.

FIGURE 6

Supplementary Figure 3: The number and percentage of severe weight gain between the INSTIs group and the non-INSTIs group in ART 96 weeks. a-b, the number of severe weight gain and non-severe weight gain in the non-INSTIs group and INSTIs group, respectively. c, the percentage of severe weight gain between non481 INSTIs and INSTIs. d-g, the number of severe weight gain and non-severe weight gain in DTG, BIC, RAL, and EVG groups, respectively. h, the percentage of severe weight gain in the four different INSTIs groups, respectively.

FIGURE 7

Supplementary Figure 4: Multivariate analyses for severe weight gain based on INSTIs or non-INSTIs regimens including PLWH with AIDS stage and non-AIDS stage.